AVTX
NASDAQAvalo Therapeutics Inc.
News25/Ratings12
News · 26 weeks108+50%
2026-03-012026-08-23
Mix4790d
- Insider23(49%)
- Other11(23%)
- SEC Filings9(19%)
- Analyst2(4%)
- Leadership2(4%)
Latest news
25 items- INSIDERChief Financial Officer Sullivan Christopher Ryan sold $1,450,419 worth of shares (72,725 units at $19.94) as part of a pre-agreed trading plan and exercised 71,852 shares at a strike of $9.88, decreasing direct ownership by 2% to 39,900 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Medical Officer Doyle Mittie exercised 1,000 shares at a strike of $12.65 and sold $20,000 worth of shares (1,000 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
- INSIDERChief Strategy Officer Riley Jennifer sold $52,012 worth of shares (2,655 units at $19.59), decreasing direct ownership by 7% to 37,041 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Medical Officer Doyle Mittie exercised 679 shares at a strike of $8.04 and sold $13,580 worth of shares (679 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
- SECSEC Form SCHEDULE 13G filed by Avalo Therapeutics Inc.SCHEDULE 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
- SECSEC Form 10-Q filed by Avalo Therapeutics Inc.10-Q - Avalo Therapeutics, Inc. (0001534120) (Filer)
- SECAvalo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
- PRAvalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business UpdatesPlans to initiate a registrational Phase 3 program evaluating abdakibart in hidradenitis suppurativa (HS) in the first half of 2027Expanded pipeline with AVTX-010, a long-acting next-generation anti-IL-1β antibody, with IND submission planned for the first half of 2027Appointed Ron Philip to the Board of DirectorsCash, cash equivalents and investments of $472.2 million as of June 30, 2026, expected to provide runway into 2029 WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced business updates
- INSIDERChief Medical Officer Doyle Mittie exercised 1,000 shares at a strike of $12.65 and sold $20,000 worth of shares (1,000 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- SECSEC Form EFFECT filed by Avalo Therapeutics Inc.EFFECT - Avalo Therapeutics, Inc. (0001534120) (Filer)
- SECSEC Form 424B3 filed by Avalo Therapeutics Inc.424B3 - Avalo Therapeutics, Inc. (0001534120) (Filer)
- PRAvalo Therapeutics to Participate in the BTIG Biotechnology ConferenceWAYNE, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will participate in the "Honing in on Hidradenitis" panel at the virtual BTIG Biotechnology Conference on Wednesday, July 29, 2026, at 10:30 am ET. Management will also host one-on-one investor meetings during the conference. Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.co
- SECSEC Form S-3 filed by Avalo Therapeutics Inc.S-3 - Avalo Therapeutics, Inc. (0001534120) (Filer)
- PRAvalo Therapeutics to Participate in the Leerink Partners Therapeutics ForumWAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will host one-on-one investor meetings during the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston. About Avalo Therapeutics Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Our lead asset, abdakibart, is an anti-IL-1β monoclonal antibody (mAb). Positive topline data was recently rep
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
- ANALYSTLeerink Partners initiated coverage on Avalo Therapeutics with a new price targetLeerink Partners initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $38.00
- INSIDERSEC Form 4 filed by Director Philip Ron M4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERSEC Form 4 filed by Director Jain Rita4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Medical Officer Doyle Mittie exercised 4,654 shares at a strike of $10.89 and sold $93,080 worth of shares (4,654 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERSEC Form 4 filed by Director Lind Kevin Robert4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- PRAvalo Therapeutics to Join the Russell 2000® and Russell 3000® IndexesWAYNE, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that it will be added to the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 26, 2026. The Russell 3000® Index measures the performance of the largest 3,000 publicly traded U.S. companies, representing approximately 96% of the investable U.S. equity market. The Russell 2000® Index is a subset of the Russell 3000® Index and serves as the leading benchmark for
AVTX FAQ
6 questionsWhere does AVTX stock trade?
Avalo Therapeutics Inc. (AVTX) is listed on NASDAQ.What sector and industry is AVTX in?
Avalo Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Avalo Therapeutics Inc. go public?
Avalo Therapeutics Inc. (AVTX) completed its IPO in 2015.What are analysts saying about AVTX?
Avalo Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $3800.00 price target on 2026-07-06. Recent price targets range from $2500.00 to $4800.00.What companies are similar to AVTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AVTX side-by-side with any of them on Quantisnow.How can I track AVTX on Quantisnow?
Quantisnow aggregates Avalo Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AVTX to receive live email and push alerts on every new disclosure.